Results 51 to 60 of about 182,433 (270)

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection [PDF]

, 2013
Background & Aims: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or ...
Simone Susser (48294), Annika Brodzinski, Thomas Berg (186372), Migaud, Pascal, Jacob George (205614), Brodzinski, Annika, Tobias Müller, Susser, Simone, Stephan Böhm (334611), Sarrazin, Christoph, Christoph Sarrazin (48298), Pascal Migaud, Schott, Eckart, Bömmel, Florian van, Heiko Witt, Florian van Bömmel, Janett Fischer, Christoph Sarrazin, Stewart, Graeme, Graeme Stewart, Witt, Heiko, Thomas Berg, Simone Susser, Balazs Fülöp, Fülöp, Balazs, Stephan Böhm, Annika Brodzinski (477753), Balazs Fülöp (477754), Müller, Tobias, Fischer, Janett, Böhm, Stephan, Berg, Thomas, Tobias Müller (163591), Janett Fischer (477751), Eckart Schott (320945), Graeme Stewart (208243), Jacob George, Heiko Witt (161481), Pascal Migaud (477752), George, Jacob, Eckart Schott, Florian van Bömmel (477755)   +41 more
core   +1 more source

Retreatment hepatitis B surface antigen clearance prediction model identifies pegylated interferon alpha candidates in chronic hepatitis B. [PDF]

World J Gastroenterol
Fu YC, Li J, Wang JY, Zhang YW, Yan F, Chen J, Du Q, Yang C, Liang J, Ye Q, Xiang HL.   +10 more
europepmc   +3 more sources

The expirience of IDEAL

Журнал инфектологии, 2014
Combination therapy with pegylated interferon-α and ribavirin is the modern standard of chronic hepatitis C treatment [1-3] in Russian Federation [4]. This particular regimen provides achieving of sustained virological response (SVR) in 42-28% of patient
E. Z. Burnevich
doaj   +1 more source

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin

Annals of Hepatology, 2010
The effect of interferon alfa against hepatitis C virus has been well documented. However, clinical efficacy is low due to the short interferon residence in the body.
Ricardo Jiménez-Méndez, Gilberto Castañeda-Hernández   +1 more
doaj   +1 more source

[Pegylation and interferons in multiple sclerosis]

Farmeconomia. Health economics and therapeutic pathways, 2016
Pegylation is a procedure used for drug development since the 1970s and consists of the conjugation of a polyethylene glycol molecule (PEG) to a drug. PEG has shown to be safe and effective in improving the pharmacokinetic and pharmacodynamic profile of drugs.
Cecilia Saleri, Diego Centonze, Giulia Vestri, Elisa Puma, Sergio Iannazzo, Luigi Giuliani, L Santoni, Pier Luigi Canonico   +7 more
openaire   +4 more sources

Interferons lambda – therapeutic application

Сибирский научный медицинский журнал, 2020
Interferons are a group of protein molecules with a broad spectrum of effects on the human body. Interferon lambda (type III interferon) was discovered comparatively recently about 20 years ago and its action is still poorly understood.
N. A. Kikhtenko, L. A. Oleynik, V. K. Makarov, E. P. Nagorskaya, P. G. Madonov   +4 more
doaj   +1 more source

Drug-resistant tuberculosis: time for visionary political leadership. [PDF]

, 2013
Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible
Abubakar, Ibrahim, Raviglione, Mario, Lipman, M, Sarda, K, Pletschette, Michel, Mchugh, Timothy D., Falzon, Dennis, Zumla, Adam, Zumla, A, Ford, Nathan, Mwaba, P, Marais, BJ, Lawn, Stephen D, Bates, M, Nahid, Payam, Logan, S, Masham, Susan, McHugh, Timothy D, Masham, S, McNerney, R, Schito, M, Adetifa, I, Hafner, Richard, Adetifa, L, Zignol, M, Lipman, Marc, Falzon, D, Ditiu, L, Memish, ZA, Mwaba, Peter, Lawn, SD, Kim, P, Cole, Stewart, Zijenah, Lynn, Raviglione, M, Zignol, Matteo, Cox, Helen, Bates, Matthew, Adetifa, Ifedayo, Ditiu, Lucica, Sarda, Krishna, Cox, H, McHugh, TD, McNerney, Ruth, Nahid, P, Abubakar, I, Migliori, Giovanni Battista, Ford, N, Lawn, S D, Hoelscher, Michael, Kim, Peter, Hafner, R, Memish, Ziad A, Maeurer, Markus, Marais, B J, Zijenah, L, Memish, Z A, Maeurer, M, Migliori, G B, Marais, Ben J., Logan, Simon, Hoelscher, M, McHugh, T D, Marais, Ben J, Zumla, Alimuddin, Cole, S, Lawn, Stephen D., Migliori, GB, Schito, Marco, Pletschette, M, Memish, Ziad A.   +70 more
core   +1 more source

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

Revista do Instituto de Medicina Tropical de São Paulo, 2019
Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment ...
Marcos Mucenic, Ajacio Bandeira de Melo Brandão, Claudio Augusto Marroni, Alfeu de Medeiros Fleck Junior, Maria Lucia Zanotelli, Ian Leipnitz, Mário Henrique Meine, Guillermo Kiss, Juliano Martini, Eduardo Soares Schlindwein, Ane Micheli Costabeber, Fernanda Karlinsky Rodrigues Sacco, Giovana Rossato, Guido Pio Cracco Cantisani   +13 more
doaj   +1 more source

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms [PDF]

, 2011
Background: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C.
Askarieh Galia, Neumann, A.U. (Avidan), Söderholm, Jonas,, Magnus Lindh, Avidan U Neumann, Stephanie Bibert, Soderholm, J, Askarieh, Galia,, Romero, A. (Ana), Group, DITTO-HCV Study, Jean-Michel Pawlotsky, Lindh, M., Negro, F, Söderholm, J., Lindh, M, Missale, Gabriele, Lagging, Martin,, Askarieh, G., Haagmans, Bart L, Romero, Ana, Hellstrand, K. (Kristoffer), Bochud Pierre-Yves, Lagging, Martin, Romero, A, null null, Söderholm Jonas, Haagmans, Bart L., Neumann, AU (Avidan), Gabriele Missale, Ferrari, C., Negro, F., Pawlotsky, J.M., Lindh Magnus, Negro Francesco, Avidan U. Neumann, Pierre-Yves Bochud, Lindh, Magnus, Johan Westin, Zeuzem Stefan, Lindh, M. (Magnus), Missale Gabriele, Bochud, Pierre Yves, Bibert, S., Bochud, P.Y., Galia Askarieh, Lagging Martin, Ferrari Carlo, Bibert, Stephanie, Hellstrand, Kristoffer, Zeuzem, S., Neumann, Avidan U., Haagmans, B.L., DITTO-HCV Study Group, Neumann, A.U., Lindh, Magnus,, Francesco Negro, Westin, J., Söderholm, J. (Jonas), Zeuzem, S. (Stefan), Söderholm, Jonas, Ferrari, Carlo, Martin Lagging, Neumann Avidan U., Zeuzem, Stefan, Neumann, Avidan U, Zeuzem, S, Hellstrand Kristoffer, Westin, Johan, Bart L Haagmans, Romero, A., Lagging, M. (Martin), Hellstrand, K., Haagmans, Bart, Bibert Stephanie, Hellstrand, K, Bart L. Haagmans, Missale, G. (Gabriele), Pawlotsky, Jean Michel, Pawlotsky, Jean-Michel, Ferrari, C. (Carlo), Carlo Ferrari, Bochud, P-Y. (Pierre-Yves), Haagmans Bart L., Askarieh, G, Lagging, M., Missale, G., Stefan Zeuzem, Kristoffer Hellstrand, Ferrari, C, Westin, J. (Johan), Askarieh, Galia, Bibert, S, Lagging, M, Westin, Johan,, Hellstrand, Kristoffer,, Westin, J, Haagmans, B.L. (Bart), Romero Ana, Jonas Söderholm, Pawlotsky Jean-Michel, Westin Johan, Askarieh, G. (Galia), Negro, Francesco, Bochud, PY, Bochud, Pierre-Yves, Pawlotsky, JM, Pawlotsky, J-M. (Jean-Michel), Missale, G, Romero, Ana,, Ana Romero   +109 more
core   +1 more source

Evaluation of the long-term outcomes of patients with hepatitis delta

Journal of Infection in Developing Countries
Objective: To evaluate the long-term outcomes of hepatitis delta patients, including cirrhosis and hepatocellular carcinoma (HCC), based on clinical and laboratory data.
Muhammet Salih Tarhan, Habip Gedik, Kadriye Kart-Yasar   +2 more
doaj   +1 more source